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Mononuclear phagocyte functionand differentiation can bemodulated by specific
interactions of plasma membrane receptors with components of the extracellular
matrix, in particular, fibronectin (Fn) (1, 2) . Some of these receptors recognize the
RGDS (Arg-Gly-Asp-Ser) sequence ofthe cell-binding domain (3) . These receptors
belong to the integrin family and have been recently isolated and partially charac-
terized (4, 5) . Other regions of Fn, particularly within the Hep 11 domain and the
type III connecting segment (IIICS), contribute to the attachment and spreading
of various cells, and may be correlated with different stages of cell differentiation
(reviewed in reference 6) .
Interaction ofmonocytes and macrophages with domains ofFn that do not con-
tain RGDS has not been thoroughly investigated because these cells firmly adhere
to plasticand glass surfaces in the absence ofspecific ligands. We have used the monocy-
toid cell line U937, which does not adhere effectively to plastic surfaces, but adheres
to substrata coated withFn or withRGDS-containing fragments ofFn (4), as amodel
to study domain specificity ofmononuclear phagocytes towards Fn . The present re-
port shows that in addition to this prototype interaction, U937 cells bind efficiently
to a38-kD heparin-binding fragment derived from the A chain ofFn. It also shows
that this cell-binding site is located within the IIICS region ofFn . Binding to IIICS
is specific and independent of the RGDS-containing Fn domain .
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Materials and Methods
BriefDefinitive Report
Antibodies.
￿
mAbs N-288, N-294, and N-296 were purchased from Mallinckrodt (Mary-
land Heights, MO), and rabbit IgG anti-Fn was from CooperBiomedical, Inc . (Malvern, PA) .
Synthetic Peptides.
￿
The peptides GRGDSPC and GRGESP, corresponding to sequences
ofthe central cell-binding domain of Fn, were purchased from Peninsula Laboratories, Inc .
(Belmont, CA) and from Peptides International, Inc. (Louisville, KY) . Three overlapping
peptides, CS-1, CS-2, and CS-3 (Fig. 1), were synthesized at the Microchemistry Laboratory
ofthe New York Blood Center byDr. Robert Fields, using a peptide synthesizer (9600 ; Bio-
This work was supported by grants AI-19751 (C . Bianco) and HL-33860 (A . Garcia-Pardo) from the
National Institutes of Health . O. C . Ferreira is a recipient of a fellowship from Conselho Nacional de
Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil .
Address correspondence to Orlando C . Ferreira, Jr ., Mononuclear Cell Biology, The Lindsley F.
Kimball Research Institute, The New York Blood Center, 310 East 67th Street, New York, NY 10021 .
J . EXP . MED. ® The Rockefeller University Press - 0022-1007/90/01/0351/06 $2.00
￿
351352
￿
FERREIRA ET AL.
￿
BRIEF DEFINITIVE REPORT
search Inc., San Rafael, CA), and spanned the 67 amino acids of the IIICS region of the
38-kD domain (7, 8).
Purification of TrypticFragmentsfrom Fn.
￿
Human plasma Fn was the generous gift of Drs.
B. Horowitz and R. Shulman (New York Blood Center, NY). Fragments of 80, 58, and 38
kD (Fig. 1) were prepared by trypsin digestion (1 :200 [wt/wt], 90 min, 37 1C) as described
(4, 7). The 31- and 29-kD fragments were isolated by mild tryptic digestion (1 :1,000 [wt/wt],
15 min, room temperature) and purified as described (9). The 58-kD fragment was isolated
by affinity chromatography on heparin-Sepharose (Pharmacia Fine Chemicals, Piscataway,
NJ) and further purified on a DEAE-Sephacel column (Pharmacia Fine Chemicals) equi-
librated with 10 mM Tris, 2 M urea, pH 7.0. The fragment was eluted by addition of 0.08 M
NaCl to the startingbuffer. Fn and fragments were dialyzed against PBS and stored at - 70'C
until use. The purified fragments migrated as a single band on SDS-PAGE (not shown).
Cell Culture.
￿
The human monocytoid cell line U937, obtained from the American Type
Culture Collection (Rockville, MD), was maintained in RPMI 1640 supplemented with 10 %
heat-inactivated FCS (Irvine Scientific, Santa Ana, CA). After 3-4 d of incubation at 37°C
in a 6% C02 humidified atmosphere, cells were washed three times with RPMI and
resuspended in RPMI with 1% BSA and 10 mM Hepes (attachment medium).
Cell Attachment Assays.
￿
Assays were performed on 96-well Linbro plates (Flow Laborato-
ries, McLean, VA) with flat bottoms. Wells were coated with 100 al of a dilution of Fn or
of its fragments for 2 h at room temperature, as described (4). In some experiments, the
amounts of protein bound to the plate were determined using 3H-labeled fragments. After
coating, the plates were rinsed with PBS, bound proteins were solubilized with 0.5 N NaOH
containing 1% SDS, mixed with scintillation fluid, and counted. For inhibition experiments,
5 x 105 cells in 0.4 ml of attachment buffer were incubated with soluble Fn, Fn fragments,
or synthetic peptides for 30 min at room temperature in a rotary mixer. The suspension was
diluted to 1 ml, and 100 A1 was added to each precoated well. Inhibition of cell attachment
by antibodies to Fn was determined after incubation of plates coated with Fn or with the
38-kD fragment with 50 11 of the antibody dilution for 30 min at room temperature.
Other Methods.
￿
SDS-PAGE, Western blot analysis, and 3H-labeling of Fn fragments were
carried out as described (4). NH2-terminal amino acid sequences were determined at the
Microchemistry Laboratory, using a liquid-phase sequencer (477A; Applied Biosystems, Inc.,
Foster City, CA).
Results
Characteristics of the Fn Fragments.
￿
Fig. 1 displays the position, ligand specificity,
and NH2-terminal amino acid sequence of the Fn fragments used in this study.
Trypsin digestion of Fn releases two different fragments containing the Hep II do-
main, with molecular masses of38 and 58 kD, respectively (7, 10, 11). The difference
occurs because only the A chain of Fn contains the IIICS region (12). The 38-kD
fragment comprises the first 67 amino acids of IIICS (7) and is derived from the
A chain. The 38- and the 58-kD fragments have identical NH2-terminal sequences.
The 58-kD fragment is derived from the B chain, does not contain the trypsin-cleavage
site present in the 38-kD fragment, and lacks the entire IIICS region (10-12). It con-
tains the Fib II domain, has slower mobility on SDS-gels upon reduction, and reacts
with N-296 mAb (data not shown).
Attachment of U937 Cellsto Fn anditsFragments.
￿
U937 cells attached to plastic wells
coated with Fn, and 80- and 38-kD fragments in a dose-dependent manner (Fig.
2). The calculated concentrations required for 50% cell attachment were 14 nM
(Fn), 70 nM (80 kD), and 50 nM (38 kD), indicating that the two fragments had
similar attachment activity, but were four- to fivefold less effective than intact Fn.
Thus, U937 cells interact with two different domains of Fn. U937 did not bind toFERREIRA ET AL .
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uncoated wells or to wells coated with the 29-, 31-, or 58-kD fragments . When 2 .0
..g/cm2 of 3H-labeled 80-, 58-, and 38-kD fragments were applied to the plates, 0.18,
0.25, and 0.31 14g/cm2, respectively, bound to the wells. This indicates that the lack
of adhesion-promoting activity of the HAD fragment was not the result of poor
adsorption to the plastic .
The38-kDFragment Contains an RGDS-independent CellAttachment Domain.
￿
The fol-
lowing reagents were used in inhibition experimentsto assess the specificity ofU937
cell attachment to surfaces coated with 38-kD fragments : (a) anti-Fn antibodies ; (b)
RGD-containing synthetic peptides ; and (c) Fn and Fn fragments .
The N-294 mAb, directed to the cell-binding domain of Fn, did not affect U937
adhesion to the 38-kD fragment, but inhibited cell attachment to Fn-coated plates
(not shown) . The mAb N-296, specific for the COOH-terminal domain, had no
effect . Cell adhesion to 38-kDfragment- or to Fn-coatedplates wascompletely abol-
ished by small doses of a polyclonal rabbit IgG anti-Fn . Thus, U937 recognized 38-
kD determinants that were distinct from those of the cell-binding domain. The amount
ofimmobilized Fn (and thereforeof antibody)wasprobably insufficient topromote
Fc-mediated cell adhesion .
Preincubation ofU937 cells with the synthetic peptideGRGDSPC inhibited cell
attachment to Fn-coated substrata (Fig . 3 A), but had no effect on adhesion to 38-
FIGURE 1 . Model of human
plasmaFn showing the location
ofbiologically active domains .
Theshaded boxes represent the
tryptic fragments used in this
study. The NH2-terminal ami-
no acid sequence of the fragments
was : 29 kD, <EAQQMVQP-
QSP; 31 kD, HRPRPYPPNV;
38 kD, TAGPDQTEMTIE ; 58
kD, TAGPDQTEMTIE; and
80 kD, SD()VPSPR()L . An
asterisk marks the position of
theRGDS . Thedarkened area
IIICS is present only on the A
chain, and on the 38- and 31-
kD fragments .The 38-kD frag-
ment contains the first 67 amino
acid residues ofIIICS; the three
overlapping synthetic peptides,
CS-1, CS-2, and CS-3, were
based on this sequence.
FIGURE 2 .
￿
Attachment ofU937 cells to Fn and its frag-
ments . Microtiter wells were coated with Fn or its frag-
ments . Cells (5 x 104/well) were added and the plates
incubated at 37°C for 30 min. Cell attachment was
quantified after washes, as described in Materials and
Methods . Values are the average number of cells at-
tached/well in at least three separate experiments.354
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kD-coated wells (Fig. 3 B). The control peptide GRGESP had no effect in either
case. Preincubation of U937 cells with the soluble 38-kD fragment abolished cell
attachment to 38-kD-coated wells (Fig. 3 C); preincubation with Fn or withthe 80-
kD fragment had no effect. These results indicated that U937 interaction with the
38-kD domain did notinvolve the RGDS sequence or thecellsurface receptors that
recognize this region.
The relative contribution ofthe fragments to U937 adhesionto Fn was evaluated
using 38- and 80-kD fragments and intact Fn as soluble inhibitors. Preincubation
of U937 with 1.2 mg/ml ofthe 80-kD fragment reduced cell attachment to Fn by
90% (Fig. 3 D). The 38-kD fragment produced 55% inhibition at the same dose.
The 80-kD fragment was 30-fold more effective in producing half-maximal inhibi-
tion thanthe 38-kDfragment (0.38 vs. 12 pM). Preincubation ofthe cells with soluble
Fnhad no effect on their subsequentadhesion to Fn-coatedwells, inagreement with
previously reported results (4).
Identification oftheRegion ofthe38-kDDomain thatPromotes CellAdhesion.
￿
U937 cells
bound to wells coated with the 38-kD fragment, but did not bind to wells coated
with the 58-kD fragment, suggesting that cell attachmentmightbe mediated bythe
unique IIICS region ofthe A chain, absent from the 58-kD fragment. To confirm
this observation andlocate the binding region, syntheticpeptides representing three
regions ofIIICS were used as inhibitory probes in cell attachmentassays. The CS-1
peptide (residues 1-25) inhibited attachment ofU937 to 38-kD-coated substrata in
a dose-dependent manner (Fig. 4 A). This effect could be reversed by increasing
the concentration of substratum-bound 38-kD fragments (not shown). The other
two peptides, CS-2 (residues 22-46) and CS-3 (residues 43-67), had no effect. None
of the peptides inhibited attachment of U937 cells to Fn-coated wells (Fig. 4 B).
Discussion
The major conclusions ofthis report are: (a) a 38-kD heparin-binding fragment,
derived from the A chain of Fn, supports adhesion ofU937 cells as effectively as
1250
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￿
FIGURE 3.
￿
Inhibition of U937 attachment
to 38-kDfragment-(A and C andto Fn- (B
and D) coated wells. The synthetic peptides
380
￿
GRGDSPC and GRGESP (A and B) or
I
￿
solubleFn and Fn fragment- (CandD) were
used as inhibitors. Cells were incubated for
30 minwith peptide, Fn, or80-or 38-kDfrag
ments, and added to 38-kD fragment-(0.62
Wg/cm2) or Fn- (1.25 14g/cm2) coated wells.
Theaverage number ofattached cells in con-
38kD
￿
trol wells was 24,624 (A), 18,360 (B), 27,364
t
￿
(C, and 20,844 (D). Values represent theav-
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FIGURE 4.
￿
Inhibition ofattachment
ofU937 cells by thesynthetic peptides
CS-1, CS-2, and CS-3. Wells were
coated with the38-kDfragment (0.42
wg/cm2) (A) or with Fn (1.25 pg/cm2)
(B). U937 cells were incubated with
each peptide, and added to the coated
wells. Theaverage numberofattached
cells on control wells was 20,368 (A)
and16,675 (B). Values representtheav-
erage of two separate experiments.
the 80-kD fragment containing the RGDS cell-binding domain; (6) U937 cells in-
teract independently with the 38-kD and with the 80-kD Fn fragments; (c) the cell
attachment site of the38-kD fragment is located within thefirst 25 amino acid residues
of the IIICS region of the A chain of Fn.
U937 interaction with the 38-kD fragment did not involve recognition of RGDS,
because the 80-kD fragment and the RGDS-containing peptide did not inhibit cell
attachment to 38-kDfragment-coatedwells. Consequently, the 38-kD fragment con-
tains a second interacting site for U937 cells. The experiments described also sug-
gest that the heparin-binding site of the 38-kD fragment is not involved in U937
adhesion, because two other fragments, the 29-kD fragment containing the Hep I
domain, and the 58-kD fragment containing the Hep II domain, failed to support
cell attachment.
The synthetic peptides CS-1, CS-2, and CS-3 allowed mapping of the U937 at-
tachment site to the first 25 amino acid residues of the IIICS region. This region
was previously shown to mediate attachment and spreading of murine melanoma
and avian neural crest cells (6).
The presence of different cell-binding sites on Fn may have distinct functional
significance. For example, cell interactions with a second Fn site may regulate the
delivery of intracellular signals. In addition, the sequence of the CS-1 peptide can
be present or absent from Fn subunits, dueto alternative splicing mechanisms (12).
Fibroblasts, the major producers of cellular Fn, can synthesize Fn molecules with
andwithout CS-1. Therefore, fibroblasts couldplay arole in theregulation ofmono-
cyte interactions with extracellular matrices by varying the type of Fn deposited.
Plasma Fn contains both cell-binding sites, the RGDS and the CS-1. Thus, extrava-
sation ofplasma Fn during inflammatory processes generates auniformmatrix with
high attachment capacity for monocyte accumulation and differentiation. Future
studies of the tissue distribution of Fn forms, and of the functional consequences
of the interaction of monocytes with CS-1, mayhelp in the elucidation of molecular
mechanisms that modulate the behavior of mononuclear phagocytes.
Summary
U937 cells attach to the RGDS-containing 80-kD fragment of fibronectin (Fn).
The present report examined whether these cells recognize other domains of Fn.
U937 cells attach to a 38-kD fragment derived from the A chain of Fn, which in-
cludes the Hep 11 domain and most of the alternatively spliced IIICS region. U937356
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did not bind to a 58-kD fragment derived from the B chain (which lacks IIICS)
and has the Hep II site. They also did not bind to a 31-kD COOH-terminal fibrin-
binding fragment or to a 29-kD fragment containing the Hep I domain. Cell adhe-
sion to the 38-kD fragment was not inhibited by the 80-kD fragment, by GRGDSPC
synthetic peptides, or by a mAb directed to the RGDS-containing domain of Fn.
Attachment was completely inhibited by the 38-kD fragment and by the synthetic
peptide CS-1, comprising the first 25 amino acid residues of IIICS. These results
indicate that U937 cells interact with two sites ofFn, the RGDS-containing region,
and the IIICS region.
The authors thank Dr. Jay E. Valinsky for his helpful suggestions; Judy Miller, Donna Strauss,
and Kristine E. Sheridan for their expert technical assistance; and Samuel Barninger for
help in the preparation of the manuscript.
Receivedfor publication 19 June 1989 and in revisedform 21 September 1989.
References
1 . Bianco, C . 1983. Fibrin, Fibronectin and Macrophages. Ann. NY Acad Sci. 408:602.
2 . Bevilacqua, M. P, D. Amrani, M. W. Mosesson, and C. Bianco. 1981 . Receptors for
cold-insoluble globulin (plasma fibronectin) on human monocytes.J Exp. Med. 153 :42.
3 . Wright, S. D., and B. C. Meyer. 1985. Fibronectin receptor ofhuman macrophages recog-
nizes the sequence Arg-Gly-Asp-Ser. J. Exp. Med. 162:762 .
4. Garcia-Pardo, A., O. C. Ferreira, J. Valinsky, and C. Bianco. 1989. Fibronectin receptors
ofmononuclear phagocytes: binding characteristics and biochemical isolation. Exp. Cell
Res. 181:420.
5 . Brown, E. J., andJ. L. Goodwin. 1988. Fibronectin receptors of phagocytes. Character-
ization of the Arg-Gly-Asp binding proteins ofhuman monocytes and polymorphonuclear
leukocytes. J. Exp. Med. 167 :777.
6. Yamada, K. M. 1989. Fibronectin domains and receptors. In Fibronectin. D. F. Mosher,
editor. Academic Press, New York. 47-121 .
7. Garcia-Pardo, A., A. Rostagno, and B. Frangione. 1987. Primary structure of human
plasma fibronectin. Characterization of a 38 kDa domain containing the C-terminal
heparin-binding site (Hep III site) and a region of molecular heterogeneity. Biochem. J.
241:923.
8. Humphries, M. J., A. Komoriya, S. K. Akiyama, K. Olden, and K. M. Yamada. 1987.
Identification oftwo distinct regions of the type III connecting segment ofhuman plasma
fibronectin that promote cell type-specific adhesion. J Biol. Chem. 262:6886.
9. Garcia-Pardo, A., E. Pearlstein, and B. Frangione. 1985. Primary structure of human
plasma fibronectin. Characterization of a 31,000-dalton fragment from the COOH-
terminal region containing a free sulfhydryl group and a fibrin-binding site.j Biol. Chem.
260 :10320.
10. Hayashi, M., and K. M. Yamada. 1983 . Domain structure of the carboxyl-terminal half
of human plasma fibronectin. J Biol. Chem. 258:3332.
11 . Sekiguchi, K., and S. 1. Hakomori. 1983. Domains structure ofhuman plasma fibronectin.
Differences and similarities between human and hamster fibronectins. J Biol. Chem.
258:3967.
12 . Kornblihtt, A. R., K. Umezawa, K. Vibe-Pedersen, and F. E. Baralle. 1985. Primary
structure of human fibronectin: differential splicing may generate at least 10 polypep-
tides from a single gene. EMBO (Eur Mol. Biol. Organ.)j 4:1755.